×
About 4,075 results

ALLMedicine™ CAR T-cell Therapy Center

Research & Reviews  702 results

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT05237986

Aug 12th, 2022 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...

Assessing the Role of Radiotherapy in Patients with Refractory or Relapsed High-Grade B...
https://doi.org/10.1016/j.radonc.2022.08.007
Radiotherapy and Oncology : Journal of the European Socie... Ababneh HS, Abramson JS et. al.

Aug 12th, 2022 - An estimated 30-40% of patients with diffuse large B cell lymphoma (DLBCL) will either relapse or have refractory disease with first-line chemoimmunotherapy. The standard approach for relapsed/refractory disease is salvage chemotherapy followed by...

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT04409314

Aug 11th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the incidence of intratumoral hypoxia in patients with relapsed or refractory (R/R) malignancies before treatment with chimeric antigen receptor (CAR) T-cell therapy. SECONDARY OBJECTIVE: I. To evaluate the associ...

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05495464

Aug 11th, 2022 - PRIMARY OBJECTIVES: To determine the safety profile of the acalabrutinib plus rituximab combination followed by CAR T-cell therapy in newly diagnosed high risk MCL patients. SECONDARY OBJECTIVES: To evaluate efficacy measured by complete response ...

A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah®) in Relapsed/Refractory Large B-cell Lymphoma Subjects
https://clinicaltrials.gov/ct2/show/NCT05075603

Aug 10th, 2022 - This is a multicenter Phase 1b study evaluating the safety, tolerability and preliminary anti-tumor activity of NT-I7 administration following SOC Kymriah CAR T-cell therapy for eligible subjects with r/r LBCL. The study consists of a Dose Escalat...

see more →

Guidelines  2 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220575
Bone Marrow Transplantation; Ljungman P, Mikulska M et. al.

May 15th, 2020 - The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic c...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  35 results

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT05237986

Aug 12th, 2022 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT04409314

Aug 11th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the incidence of intratumoral hypoxia in patients with relapsed or refractory (R/R) malignancies before treatment with chimeric antigen receptor (CAR) T-cell therapy. SECONDARY OBJECTIVE: I. To evaluate the associ...

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05495464

Aug 11th, 2022 - PRIMARY OBJECTIVES: To determine the safety profile of the acalabrutinib plus rituximab combination followed by CAR T-cell therapy in newly diagnosed high risk MCL patients. SECONDARY OBJECTIVES: To evaluate efficacy measured by complete response ...

A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah®) in Relapsed/Refractory Large B-cell Lymphoma Subjects
https://clinicaltrials.gov/ct2/show/NCT05075603

Aug 10th, 2022 - This is a multicenter Phase 1b study evaluating the safety, tolerability and preliminary anti-tumor activity of NT-I7 administration following SOC Kymriah CAR T-cell therapy for eligible subjects with r/r LBCL. The study consists of a Dose Escalat...

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05202782

Aug 3rd, 2022 - PRIMARY OBJECTIVE: I. To determine efficacy of adjunctive zanubrutinib with chimeric antigen receptor T (CAR T)-cell therapy as defined by an improvement in 6-month complete response rates (CR) (defined per 2014 Lugano criteria) as compared to his...

see more →

News  889 results

Multiple Myeloma Therapies: A Glimpse Into the Future
https://www.medscape.com/viewarticle/964340

Aug 10th, 2022 - This transcript has been edited for clarity. Joseph Mikhael, MD: Hello. My name is Dr Joseph Mikhael and welcome to Medscape InDiscussion: Multiple Myeloma. Today, we're talking about future therapies in multiple myeloma. I've had the privilege of...

CAR T-Cell Therapy Turns 10 and Finally Earns the Word 'Cure'
https://www.medscape.com/viewarticle/977665

Jul 21st, 2022 - Ten years ago, Stephan Grupp, MD, PhD, plunged into an unexplored area of pediatric cancer treatment with a 6-year-old patient for whom every treatment available for her acute lymphoblastic leukemia (ALL) had been exhausted. Dr Stephan Grupp Grupp...

Patients Waiting Months for 'Last Chance' CAR T-Cell Therapy
https://www.medscape.com/viewarticle/977179

Jul 14th, 2022 - Some patients with blood cancers for whom all other therapeutic options have been exhausted have one final chance of getting rid of their disease ― treatment with chimeric antigen-receptor (CAR) T cells. Described as a "living drug," the treatment...

New CAR-T Therapy Elicits Strong Response in Multiple Myeloma
https://www.medscape.com/viewarticle/975749

Jun 16th, 2022 - All 30 patients with relapsed/refractory multiple myeloma who received a new CAR T-cell therapy, ARI0002h, responded to the investigational agent, with almost two thirds achieving complete remission at 16 months, new data show. Most patients did n...

CAR T-Cell Therapy May Represent a New Option in Medullary Thyroid Cancer
https://www.onclive.com/view/car-t-cell-therapy-may-represent-a-new-option-in-medullary-thyroid-cancer

May 5th, 2022 - Investigators at the Perelman School of Medicine at the University of Pennsylvania (Penn) have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with ad...

see more →